Promises
2 promises
Promise Tracker
0 delivered, 0 close, 2 missed.
View Promises →
Aurobindo Pharma Limited — Q4 FY24
Aurobindo Pharma delivered a strong Q4 FY24 with revenue of INR 7,850 crore (+17% YoY) and EBITDA of INR 1,687 crore (+68% YoY), driven by volume gains, new product launches, stable pricing, and raw material cost softening.
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Aurobindo Pharma delivered a strong Q4 FY24 with revenue of INR 7,850 crore (+17% YoY) and EBITDA of INR 1,687 crore (+68% YoY), driven by volume gains, new product launches, stable pricing, and raw material cost softening. EBITDA margin expanded 680 bps YoY to 22.3%, while PAT grew 80% to INR 909 crore. US formulation revenue rose 22% to INR 3,588 crore, and Europe grew 10% to INR 1,832 crore. Management guided for FY25 EBITDA margin of 21%-22%, supported by ramp-up of Pen-G and 6-APA facilities, though Eugia 3's OAI status poses a near-term risk to injectable growth. Biosimilar pipeline advances with trastuzumab filing in US expected within 3 months. Key risk: Eugia 3 remediation may delay approvals and impact injectable revenue trajectory.
औरोबिंदो फार्मा ने चौथी तिमाही में अच्छा प्रदर्शन किया। कंपनी की कमाई 7,850 करोड़ रुपये रही, जो पिछले साल से 17% ज्यादा है। मुनाफा 80% बढ़कर 909 करोड़ रुपये हो गया। यह बढ़त ज्यादा बिक्री, नए उत्पादों और कच्चे माल की कीमतों में कमी से आई। अमेरिका में दवाओं की बिक्री 22% और यूरोप में 10% बढ़ी। कंपनी को अगले साल 21-22% मुनाफा मार्जिन की उम्मीद है। लेकिन यूजिया 3 प्लांट पर नियामकीय पाबंदी से इंजेक्टेबल दवाओं की बिक्री पर खतरा है। बायोसिमिलर दवा ट्रास्टुजुमैब जल्द अमेरिका में दाखिल होगी।
Promises0 met · 2 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Risks
4 risks
Risk Intelligence
Eugia 3 OAI status may delay ANDA approvals
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
US Formulation Revenue (Constant Currency)
$432M
+20% YoY
US formulation revenue grew 20% YoY in constant currency, driven by volume gains and new launches.
Global Injectable & Specialty Sales
$143M
+26% YoY
Global injectable and specialty sales grew 26% YoY, though QoQ decline due to Eugia 3 shutdown.
ANDAs Filed (Q4)
11
N/A
Filed 11 ANDAs in Q4; total ANDA filings stand at 830 as of March 31, 2024.
Pen-G Project CapEx (Cumulative)
$285M
N/A
Cumulative CapEx for Pen-G project reached $285 million; commercialization started in Q4.
What Changed vs Last Quarter
NEW
Pen-G and 6-APA meaningful contribution from Q3 FY25
Pen-G and 6-APA facilities will start meaningful contribution from Q3 FY25, with full ramp-up expected by September 2024.
NEW
Eugia global revenue run rate of $150M per year
Eugia expects to maintain a global revenue run rate of $150 million per year, with US contributing $100-$110 million.
NEW
Biosimilar trastuzumab US filing within 3 months
Trastuzumab biosimilar to be filed with US FDA within the next 3 months, following a successful Type 4 pre-submission meeting.
UPDATED
FY25 EBITDA margin target of 21%-22%
Management expects EBITDA margin to improve to 21%-22% in FY25, driven by operating leverage and ramp-up of new capacities.
DROPPED
Eugia Unit III production restart timeline
Non-aseptic lines expected to restart by end of February 2024; aseptic lines within 1-2 months; full production by end of FY24.
DROPPED
China plant revenue generation from Q1/Q2 FY25
The China oral solids plant has received cGMP approval and is expected to start generating revenue from Q1 or Q2 of FY2025.
DROPPED
Biosimilar Xolair revenue guidance of $120M-$180M by 2028
Management guided Xolair biosimilar revenue potential of $120M-$180M by 2028, assuming approvals in US and Europe.
NEW RISK
Eugia 3 OAI status may delay ANDA approvals
Eugia 3 plant classified as OAI; 29 pending ANDAs may be stuck for at least 1 year, impacting injectable growth.
NEW RISK
Biosimilar monetization timeline pushed to 2027-2028
Management expects meaningful biosimilar revenue only by 2027-2028, later than some investor expectations.
NEW RISK
Pen-G ramp-up complexity may delay benefits
Pen-G fermentation is complex; yield optimization will only be addressed by September, posing execution risk.
NEW RISK
Ryzneuta launch in US faces competitive pressure
Management is conservative on Ryzneuta (pegfilgrastim biosimilar) launch, citing multiple competitors and uncertain pricing.
RISK GONE
Eugia Unit III FDA observations and production halt
FDA issued Form 483 with 9 observations at Eugia Unit III; manufacturing paused, expected $20M revenue impact in Q4. Risk of prolonged shutdown and market share loss.
RISK GONE
Potential market share loss in injectable products
Analyst raised concern about losing market share in key products from Eugia Unit III; management acknowledged risk but expects to recover with existing stock and phased restart.
RISK GONE
Penicillin G plant pricing risk
Analyst questioned profitability if Pen G prices fall below $20/kg; management deferred response, indicating uncertainty.
RISK GONE
Biosimilar commercialization delays
Pneumococcal vaccine missed national tender timeline; management indicated no near-term market entry, highlighting execution risk in biosimilar launches.
🤫 Topics management stopped discussing
Mentioned in Q1 FY24, Q2 FY24
On track to achieve $560 million globally for Eugia Specialities in FY24, driven by injectable growth.
Fast read
Guidance and risk preview
Management expects EBITDA margin to improve to 21%-22% in FY25, driven by operating leverage and ramp-up of new capacities.
Eugia 3 plant classified as OAI; 29 pending ANDAs may be stuck for at least 1 year, impacting injectable growth.
View Risks →